On Thursday, Vivani Medical, Inc. (NASDAQ:VANI) announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the LIBERATE-1 trial in Australia. Vivani's lead program, NPM-115, ...
Wednesday, Vivani Medical Inc (NASDAQ:VANI) released preclinical data on weight loss effects for NPM-115, the company’s miniature, twice-yearly exenatide subdermal implant under development for ...
Appointment comes as Vivani prioritizes the development of its GLP-1 implants for the treatment of obesity and chronic weight management Under Bradbury’s leadership as CEO, Amylin Pharmaceuticals, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback